Pharmacological studies also show that NRF2 can be therapeutically activated (e.g., by dimethyl fumarate), and such activation confers protection to both normal and vitiligo melanocytes, suggesting that the pathway remains at least partially responsive and may be modulated in a context-dependent manner [48]. This evidence concerns the gene NFE2L2 and vitiligo.